TY - JOUR
T1 - Roles of histone acetylation modifiers and other epigenetic regulators in vascular calcification
AU - Kwon, Duk Hwa
AU - Ryu, Juhee
AU - Kim, Young Kook
AU - Kook, Hyun
N1 - Publisher Copyright:
© 2020, MDPI AG. All rights reserved.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Vascular calcification (VC) is characterized by calcium deposition inside arteries and is closely associated with the morbidity and mortality of atherosclerosis, chronic kidney disease, diabetes, and other cardiovascular diseases (CVDs). VC is now widely known to be an active process occurring in vascular smooth muscle cells (VSMCs) involving multiple mechanisms and factors. These mechanisms share features with the process of bone formation, since the phenotype switching from the contractile to the osteochondrogenic phenotype also occurs in VSMCs during VC. In addition, VC can be regulated by epigenetic factors, including DNA methylation, histone modification, and noncoding RNAs. Although VC is commonly observed in patients with chronic kidney disease and CVD, specific drugs for VC have not been developed. Thus, discovering novel therapeutic targets may be necessary. In this review, we summarize the current experimental evidence regarding the role of epigenetic regulators including histone deacetylases and propose the therapeutic implication of these regulators in the treatment of VC.
AB - Vascular calcification (VC) is characterized by calcium deposition inside arteries and is closely associated with the morbidity and mortality of atherosclerosis, chronic kidney disease, diabetes, and other cardiovascular diseases (CVDs). VC is now widely known to be an active process occurring in vascular smooth muscle cells (VSMCs) involving multiple mechanisms and factors. These mechanisms share features with the process of bone formation, since the phenotype switching from the contractile to the osteochondrogenic phenotype also occurs in VSMCs during VC. In addition, VC can be regulated by epigenetic factors, including DNA methylation, histone modification, and noncoding RNAs. Although VC is commonly observed in patients with chronic kidney disease and CVD, specific drugs for VC have not been developed. Thus, discovering novel therapeutic targets may be necessary. In this review, we summarize the current experimental evidence regarding the role of epigenetic regulators including histone deacetylases and propose the therapeutic implication of these regulators in the treatment of VC.
KW - Epigenetic regulator
KW - Histone deacetylase
KW - Histone modifiers
KW - Post-translational modification
KW - Vascular calcification
KW - Vascular smooth muscle cells
UR - http://www.scopus.com/inward/record.url?scp=85084382669&partnerID=8YFLogxK
U2 - 10.3390/ijms21093246
DO - 10.3390/ijms21093246
M3 - Article
C2 - 32375326
AN - SCOPUS:85084382669
SN - 1661-6596
VL - 21
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 9
M1 - 3246
ER -